Prognostic Impact of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Uniformly Treated With R-CHOP Chemotherapy | Zendy

Juan C. Gomez-Gelvez | Zendy; Mohamed E. Salama | Zendy; Sherrie L. Perkins | Zendy; Matthew O. Leavitt | Zendy; Kedar Inamdar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prognostic Impact of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Uniformly Treated With R-CHOP Chemotherapy

Author(s) -

Juan C. Gomez-Gelvez,

Mohamed E. Salama,

Sherrie L. Perkins,

Matthew O. Leavitt,

Kedar Inamdar

Publication year - 2016

Publication title -

american journal of clinical pathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.859

H-Index - 128

eISSN - 1943-7722

pISSN - 0002-9173

DOI - 10.1093/ajcp/aqw034

Subject(s) - medicine , diffuse large b cell lymphoma , cd68 , vincristine , rituximab , oncology , lymphoma , chop , cyclophosphamide , chemotherapy , pathology , immunohistochemistry

We evaluated the prognostic impact of cell-of-origin classification as well as intratumoral regulatory T cells (Tregs), macrophages, and microvessel density (MVD) on 115 patients (74 in the training set and 41 in the validation set) diagnosed with de novo diffuse large B-cell lymphoma (DLBCL) and uniformly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research